4 April 2014 - PHARMAC is seeking feedback on a proposal to amend the listing of two tumour necrosis factor inhibitors, etanercept and adalimumab, to include funding for the treatment of pyoderma gangrenosum.

In summary, this proposal would result in access to etanercept and adalimumab being widened via Special Authority to include the treatment of pyoderma gangrenosum from 1 June 2014.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-04-04-tnf-inhibitors/